

## 5. LITERATURVERZEICHNIS

- 1 Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. *Nat Immunol* 2002;3(11):991-8.
- 2 Qin Z, Blankenstein T. A cancer immunosurveillance controversy. *Nat Immunol* 2004;5(1):3-4.
- 3 Ichim CV. Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy *J Transl Med* 2005;3:8.
- 4 Coussens LM, Werb Z. Inflammation and cancer. *Nature* 2002;420:860-7.
- 5 Prehn RT. The immune reaction as a stimulator of tumor growth. *Science* 1972;176:170-1.
- 6 Prehn RT. Immunostimulation of chemical oncogenesis in the mouse. *Int J Cancer* 1977;20:918-22
- 7 Outzen HC. Development of carcinogen-induced skin tumors in mice with varied states of immune capacity. *Int J Cancer* 1980;26:87-92.
- 8 Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. *N Engl J Med* 1986;315:1650-9.
- 9 Ehrlich, P. Über den jetzigen Stand der Karzinomforschung. *Ned. Tijdschr. Geneesk.* 1909;5:273-90.
- 10 Burnet FM. Cancer – A biological approach. 1. The process of control. *Br Med J* 1957;1:779-82.
- 11 Thomas L. Discussion. In: Lawrence HS (Ed). *Cellular and Humoral Aspects of the Hypersensitive States*, Hoeber-Harper, New York, 1959:529-32.
- 12 Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. *Science* 1974;183:534-6.
- 13 Stutman O. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous and heterozygous matings and effect of age and carcinogen dose. *J Natl Cancer Inst* 1979;2:353-8.
- 14 Penn I. Malignancies associated with immunosuppressive or cytotoxic therapy. *Surgery* 1978; 83:492-502.
- 15 Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frodin L. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. *Int J Cancer* 1995;60:183-9.
- 16 Hunig T. T-cell function and specificity in athymic mice. *Immunol Today* 1983;4:84-87.
- 17 Maleckar JR, Sherman LA. The composition of the T cell receptor repertoire in nude mice. *J Immunol* 1987;138:3873-6.
- 18 van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H. Decreased tumor surveillance in perforin-deficient mice. *J Exp Med* 1996;184:1781-90.
- 19 Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI. Differential tumor surveillance by natural killer (NK) and NKT cells. *J Exp Med* 2000;191:661-8.
- 20 Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. *J Exp Med* 2000;192:755-60.
- 21 Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN $\gamma$  receptors. *Immunity* 1994;1:447-56.

- 22 Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. *Proc Natl Acad Sci U S A* 1998;95:7556-61.
- 23 Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFN $\gamma$  and lymphocytes prevent primary tumour development and shape tumour immunogenicity. *Nature* 2001;410:1107-11.
- 24 Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. *J Exp Med* 2002;196:129-34.
- 25 Schreiber H, Nettesheim P, Lijinsky W, Richter CB, Walburg HE Jr. Induction of lung cancer in germfree, specific-pathogen-free, and infected rats by N-nitrosoheptamethyleneimine: enhancement by respiratory infection. *J Natl Cancer Inst* 1972;49:1107-14.
- 26 van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science* 1991;254:1643-7.
- 27 Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. *J Exp Med* 1996;183:725-729.
- 28 Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. *Cancer Immunol Immunother* 2005;54:187-207.
- 29 Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. *Clin Cancer Res* 2003;9:4296-303.
- 30 Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. *Science* 1996;274:94-6.
- 31 Scheibenbogen C, Lee KH, Mayer S, Stevanovic S, Moebius U, Herr W, Rammensee HG, Keilholz U. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. *Clin Cancer Res* 1997;3:221-6.
- 32 Herr W, Schneider J, Lohse AW, Meyer zum Buschenfelde KH, Wolfel T. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. *J Immunol Methods* 1996;191:131-42.
- 33 Suni MA, Picker LJ, Maino VC. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. *J Immunol Methods* 1998;212:89-98.
- 34 Letsch A, Keilholz U, Schadendorf D, Nagorsen D, Schmittel A, Thiel E, Scheibenbogen C. High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma. *Int J Cancer* 2000;87(5):659-664.
- 35 Yoo YK, Heo DS, Hata K, Van Thiel DH, Whiteside TL. Tumor-infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2. *Gastroenterology* 1990;98:259-68.
- 36 Schiltz PM, Beutel LD, Nayak SK, Dillman RO. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. *J Immunother* 1997;20:377-86.
- 37 Tsang KY, Zhu M, Nieroda CA, Correale P, Zaremba S, Hamilton JM, Cole D, Lam C, Schlom J. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. *Clin. Cancer Res* 1997;3:2439-49.

- 38 Monsurrò V, Nagorsen D, Wang E, Provenzano M, Dudley ME, Rosenberg SA, Marincola FM. Functional heterogeneity of vaccine-induced CD8<sup>+</sup> T-cells. *J Immunol* 2002;168:5933-42.
- 39 Nagorsen D, Scheibenbogen C, Thiel E, Keilholz U. Immunologic monitoring of cancer vaccine therapy. *Exp Opin Biol Ther* 2004;4:1677-84.
- 40 Nagorsen D, Marincola FM (Eds). *Analyzing T cell responses*. Springer, Dordrecht, 2005.
- 41 Nepom GT, Buckner JH, Novak EJ, Reichstetter S, Reijonen H, Gebe J, Wang R, Swanson E, Kwok WW. HLA class II tetramers: tools for direct analysis of antigen-specific CD4<sup>+</sup> T cells. *Arthritis Rheum* 2002;46:5-12.
- 42 Schmittel A, Keilholz U, Thiel E, Scheibenbogen C: Quantification of tumor-specific T lymphocytes with the ELISPOT assay. *J Immunother* 2000;23:289-95.
- 43 Brosterhus H, Brings S, Leyendeckers H, Manz RA, Miltenyi S, Radbruch A, Assenmacher M, Schmitz J. Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion. *Eur J Immunol* 1999;29:4053-9.
- 44 Nagorsen D, Wang E, Marincola FM, Even J. Transcriptional analysis of tumor-specific T-cell responses in cancer patients. *Crit Rev Immunol* 2002;22:449-62.
- 45 Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, Marincola FM. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. *J Immunol* 1999;163:6867-75.
- 46 Monsurrò V, Wang E, Yamano Y, Migueles SA, Panelli MC, Smith K, Nagorsen D, Connors M, Jacobson S, Marincola FM. Quiescent phenotype of tumor-specific T cells following immunization. *Blood* 2004;104:1970-8.
- 47 Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* 1999;401:708-12.
- 48 Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemussen AM, Rubio-Godoy V, Rimoldi D, Guillaume P, Schadendorf D, Lipp M, Dietrich PY, Cerottini JC, Thiel E, Liénard D, Romero P, Keilholz U. Circulating tumor-reactive CD8<sup>\*</sup> T cells in melanoma patients contain a CD45RA<sup>+</sup>CCR7<sup>-</sup> effector subset exerting ex-vivo tumor-specific cytolytic activity. *Cancer Research* 2002;62:1743-50.
- 49 Tang R, Beuvon F, Ojeda M, Mosseri V, Pouillart P, Scholl S. M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes? *J Cell Biochem* 1992;50:350-6.
- 50 Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. *J Pathol* 2000;192:150-8.
- 51 Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. *Cancer Res.* 1996;56:4625-9.
- 52 Salvesen HB, Akslen LA. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. *Int J Cancer* 1999;84:538-43.
- 53 Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. *Int J Urol* 2000;7:263-9.

- 54 Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. *Cancer Res* 2000;60:5857-61.
- 55 Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. *Int J Oncol* 2000;17:445-51.
- 56 Koukourakis MI, Giatromanolaki A, Kakolyris S, O'Byrne KJ, Apostolikas N, Skarlatos J, Gatter KC, Harris AL. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. *Br J Cancer* 1998;77:1696-703.
- 57 Toomey D, Smyth G, Condron C, Kelly J, Byrne AM, Kay E, Conroy RM, Broe P, Bouchier-Hayes D. Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up. *Int J Cancer*. 2003 Jan 20;103(3):408-12.
- 58 Ambe K, Mori M, Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. *Cancer* 1989;63:496-503.
- 59 Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, van de Velde CJ, van Krieken JH. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect--a histopathological and immunohistochemical study. *BMC Cancer* 2001;1:7.
- 60 Oberg A, Samii S, Stenling R, Lindmark G. Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. *Int J Colorectal Dis* 2002;17:25-9.
- 61 Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. *Oncol Rep* 2003;10:309-13.
- 62 Nakayama Y, Inoue Y, Minagawa N, Katsuki T, Nagashima N, Onitsuka K, Tsurudome Y, Sako T, Hirata K, Nagata N, Itoh H. Relationships between S-100 protein-positive cells and clinicopathological factors in patients with colorectal cancer. 2003;23:4423-6.
- 63 Lackner C, Jukic Z, Tsybrovskyy O, Jatzko G, Wette V, Hoefler G, Klimpfinger M, Denk H, Zatloukal K. Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. *Virchows Arch* 2004;445:160-7.
- 64 Dadabayev AR, Sandel MH, Menon AG, Morreau H, Melief CJ, Offringa R, van der Burg SH, Janssen-van Rhijn C, Ensink NG, Tollenaar RA, van de Velde CJ, Kuppen PJ. Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. *Cancer Immunol Immunother* 2004;53:978-86.
- 65 Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. *Trends Immunol* 2002;23:549-555.
- 66 Kreutz M, Fritzsche J, Andreesen R. Macrophages in tumor biology. In: Burke B, Lewis CE (Eds) *The Macrophage* (2nd ed.), Oxford University Press, Oxford 2002:458-89.
- 67 Anderson KV. Toll signaling pathways in the innate immune response. *Curr Opin Immunol* 2000;12:13-9.
- 68 Takeda K, Kaisho T, Akira S. Toll-like receptors. *Annu Rev Immunol* 2003;21:335-76.

- 69 Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. *Trends Immunol* 2003;4:36-43.
- 70 Denis M, Ghadirian E. Human monocyte tumouristatic ability: modulation by cytokines and tumour cell products. *Int J Immunopharmacol* 1990;12:509-13.
- 71 Kambayashi T, Alexander HR, Fong M, Strassmann G. Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. *J Immunol*. 1995;154:3383-90.
- 72 Maeda H, Kuwahara H, Ichimura Y, Ohtsuki M, Kurakata S, Shiraishi A. TGF-beta enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. *J Immunol*. 1995;155:4926-32.
- 73 Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, van Damme J, Mantovani A. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. *J Immunol* 2000;164:762-7.
- 74 Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? *J Natl Cancer Inst* 2002;94:805-18.
- 75 Scheibenbogen C, Letsch A, Schmittel A, Asemissen AM, Thiel E, Keilholz U. Rational peptide-based tumour vaccine development and T cell monitoring. *Sem Cancer Biol* 2003;13:423-9.
- 76 Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: Vaccines for solid tumours. *Lancet Oncol* 2004;5:681-9. Erratum in: *Lancet Oncol* 2005;6(1):4.
- 77 Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. *Curr Opin Immunol* 2005;17:163-9.
- 78 Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. *Nat Med* 1998;4:321-7.
- 79 Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. *Nat Med* 2004;10:909-15.
- 80 Mocellin S, Mandruzzato S, Bronte V, Marincola FM. Cancer vaccines: pessimism in check. *Nat Med* 2004;10:1278-9.
- 81 Marincola FM. A balanced review of the status T cell-based therapy against cancer. *J Transl Med* 2005;3:16.
- 82 Rosenberg, SA, Yanelli, JR, Yang, JC, Topalian, SL, Schwartzentruber, DJ, Weber, JS, Parkinson, DR, Seipp, CA, Einhorn, JH, White, DE, Treatment of patients with metastatic melanoma with autologous tumor infiltrating lymphocytes and IL-2. *J Natl Cancer Inst* 1994;86:1159-66.
- 83 Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. *Science* 2002;298:850-4.
- 84 Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. *Proc Natl Acad Sci USA* 2004;101, Suppl 2:14639-45.
- 85 Nomura T, Sakaguchi S. Naturally arising CD25+CD4+ regulatory T cells in tumor immunity. *Curr Top Microbiol Immunol* 2005;293:287-302.

- 86 Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstien B. Increase of regulatory T cells in the peripheral blood of cancer patients. *Clin Cancer Res* 2003;9:606-12.
- 87 Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. *Cancer* 2003;98:1089-99.
- 88 Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. *Clin Cancer Res* 2003;9:4404-8.
- 89 Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. *Cancer Res* 2005;65:2457-64.
- 90 Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. *Oncol Rep* 2005;14:1269-73.
- 91 Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside TL. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. *Cancer Immunol Immunother* 2005;54:1072-81.
- 92 Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, Omata H, Fujii H. CD4(+)CD25(high) regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. *Cancer Immunol Immunother* 2006;55:1064-71.
- 93 Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. *Cancer Res* 1999;59:3128-33.
- 94 Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. *J Immunol* 1999;163:5211-8.
- 95 Zou W. Regulatory T cells, tumour immunity and immunotherapy. *Nat Rev Immunol* 2006;6:295-307.
- 96 Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T, Sakaguchi S. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating FOXP3+CD25+CD4+ regulatory T cells. *J Exp Med* 2005;202:885-91.
- 97 Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. *J Exp Med* 2004;200:771-82.
- 98 Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. *Eur J Immunol* 2004;34:336-44.
- 99 Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu YX. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. *J Exp Med* 2005;201:779-91.
- 100 Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med* 2004;10:942-9.

- 101 Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K. Intraepithelial CD8<sup>+</sup> tumor-infiltrating lymphocytes and a high CD8<sup>+</sup>/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. *Proc Natl Acad Sci U S A* 2005;102:18538-43.
- 102 Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. *Clin Cancer Res* 2005;11:8326-31.
- 103 Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. *Immunity* 2004;21:137-48.
- 104 Boon T, van Baren N. Immunosurveillance against cancer and immunotherapy--synergy or antagonism? *N Engl J Med* 2003;348:252-4.
- 105 Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. *Nat Immunol* 2001;2:293-9.
- 106 Hamann D, Baars PA, Rep MHG, Hooibrink B, Kerkhof-Garde SR, Klein MR, van Lier RAW. Phenotypical and functional separation of memory and effector human CD8<sup>+</sup> T cells. *J Exp Med* 1997;186:1407-18.
- 107 Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. *J Immunol* 1995;154:3961-8.
- 108 Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, Hand PH, Schlom J, Hamilton JM. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. *Cancer Immunol Immunother* 2000;49:517-29.
- 109 Zier K, Johnson K, Maddux J-M, Sung M, Mandeli J, Eisnebach L, Schwartz M. IFN $\gamma$ -secretion following stimulation with total tumor peptides from autologous human tumors. *J Immunol Methods* 2000;241:61-8.
- 110 Bremers AJA, Andreola S, Leo E, Gallino F, Rini F, Lombardo C, Belli F, Kuppen PJK, Parmiani G, Castella C. T cell responses in colorectal cancer patients: evidence for class II HLA-restricted recognition of shared tumor-associated antigens. *Int J Cancer* 2000;88:956-61.
- 111 Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER-2/neu-derived peptide. *Proc Natl Acad Sci USA* 1995;92:432-6.
- 112 Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumorspecific cytotoxic T lymphocyte lines. *J Exp Med* 1995;181:2109-17.
- 113 Ras E, Burg SH, van der Zegveld ST, Brandt RMP, Kuppen PJK, Offringa R, Warnarr SO, van de Velde CJH, Melief CJ. Identification of potential HLA-A 0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (EPCAM) and the carcinoembryonic antigen (CEA). *Hum Immunol* 1997;53:81-9.
- 114 Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirmacher V, Umansky V. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. *Nat Med* 2001;7:452-8.
- 115 Feuerer M, Rocha M, Bai L, Umansky V, Solomayer EF, Bastert G, Diel IJ, Schirmacher V. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. *Int J Cancer* 2001;92:96-105.

- 116 Diel IJ, Cote RJ. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer. *Cancer Treat Rev* 2000;26:53-65.
- 117 Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. *Breast Cancer Res Treat* 2000;62:245-52.
- 118 Toomey D, Harmey J, Condron C, Kay E, Bouchier-Hayes D. Phenotyping of immune cell infiltrates in breast and colorectal tumours. *Immunol Invest* 1999;28:29-41.
- 119 Miconnet I, Koenig S, Speiser D, Krieg A, Guillaume P, Cerottini JC, Romero P. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. *J Immunol* 2002;168:1212-8.
- 120 Nagorsen D, Marincola FM, Kaiser HE. Bacteria-related spontaneous and therapeutic remission of human malignancies. *In Vivo* 2002;16:551-6.
- 121 Titu LV, Monson JR, Greenman J. The role of CD8(+) T cells in immune responses to colorectal cancer. *Cancer Immunol Immunother* 2002;51:235-47.
- 122 Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. *Adv Immunol* 2000;74:181-273.
- 123 Erdman SE, Rao VP, Poutahidis T, Ihrig MM, Ge Z, Feng Y, Tomczak M, Rogers AB, Horwitz BH, Fox JG. CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. *Cancer Res* 2003;63:6042-50.
- 124 Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, Banham AH, Roncador G, Montalban C, Piris MA. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. *Clin Cancer Res* 2005;11:1467-73.
- 125 Whiteside TL. The role of immune cells in the tumor microenvironment. *Cancer Treat Res* 2006;130:103-24.
- 126 Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. *Mol Cancer Res* 2006;4:221-33.
- 127 Banchereau J, Steinman RM. Dendritic cells and the control of immunity. *Nature* 1998;392:245-52.
- 128 Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. *Nat Med* 2000;6:332-6. Retraction in: Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH. *Nat Med* 2003;9:1221.
- 129 Nestle FO, Aljagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. *Nat Med* 1998;4:328-32.
- 130 Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, Wysocka M, Trinchieri G, Murphy KM, O'Garra A. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. *J Immunol* 1995;154:5071-9.
- 131 Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: TeT help via APC activation. *J Exp Med* 1996;184:747-52.
- 132 Sallusto F, Palermo B, Lenig D, Miettinen M, Matikainen S, Julkunen I, Forster R, Burgstahler R, Lipp M, Lanzavecchia A. Distinct patterns and kinetics of



- chemokines production regulate dendritic cell function. *Eur J Immunol* 1999;29:1617-25.
- 133 Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. *Nat Immunol* 2000;1:311-6.
  - 134 Hatada EN, Krappmann D, Scheidereit C. NF- $\kappa$ B and the innate immune response. *Curr Opin Immunol* 2000;12:52-8.
  - 135 Beutler B. Endotoxin, toll-like receptor 4, and the afferent limb of innate immunity. *Curr Opin Microbiol* 2000;3:23-8.
  - 136 Guha M, Mackman N. LPS induction of gene expression in human monocytes. *Cell Signal* 2001;13:85-94.
  - 137 Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. *Nat Med* 1999;5:1249-55.
  - 138 Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A\*0201-binding residues. *J Immunol* 1996;157:2539-48.
  - 139 Granucci F, Vizzardelli C, Pavelka N, Feau S, Persico M, Virzi E, Rescigno M, Moro G, Ricciardi-Castagnoli P. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. *Nat Immunol* 2001;2:882-8.
  - 140 Andrews DM, Andoniou CE, Granucci F, Ricciardi-Castagnoli P, Degli-Esposti MA. Infection of dendritic cells by murine cytomegalovirus induces functional paralysis. *Nat Immunol* 2001;2:1077-84.
  - 141 Engelmayer J, Larsson M, Subklewe M, Chahroudi A, Cox WI, Steinman RM, Bhardwaj N. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. *J Immunol* 1999;163:6762-8.
  - 142 Larsson M, Messmer D, Somersan S, Fonteneau JF, Donahoe SM, Lee M, Dunbar PR, Cerundolo V, Julkunen I, Nixon DF, Bhardwaj N. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8<sup>+</sup> T cells. *J Immunol* 2000;165:1182-90.
  - 143 Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. *J Immunother* 2001;24:363-73.
  - 144 Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. *J Clin Oncol* 2005;23:2346-57.
  - 145 Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG Jr, Pinedo HM. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. *Lancet* 1999;353:345-50.
  - 146 Harris JE, Ryan L, Hoover HC Jr, Stuart RK, Oken MM, Benson AB 3rd, Mansour E, Haller DG, Manola J, Hanna MG Jr. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. *J Clin Oncol* 2000;18:148-57.
  - 147 Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y, Li CL, Meng FJ. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. *World J Gastroenterol.* 2003;9:495-8.

- 148 Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. *Ann Oncol* 2005;16:847-62.